Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I keep thinking about the guy with the quivering voice on the conference call who tap danced around the question about Geron....It's clear he was told to say nothing. However, I sensed that he was EXCEPTIONALLY nervous about the question. If JNJ were simply still evaluating the data (like he said), then there was no need to be so nervous. Even the past job posting "screw up" wouldn't cause this nervousness for that conference call response. My feeling is that there is more at stake on the table that he needed to be very sure not to disrupt. I'm not saying buy-out, but something definitiely was up and it seemed more than simply still reviewing the data
The Week Ahead In Biotech (Sept. 16-22): Geron Corporation (NASDAQ: GERN) and Johnson & Johnson (NYSE: JNJ) are scheduled to release primary analysis of data from the Phase 2 IMbark study for Imetelstat to treat myelofibrosis
https://finance.yahoo.com/news/week-ahead-biotech-sept-16-182216424.html
One more time for the chickens,check the call option money available.Nobody is always right but I have over 30yrs experience with equity options and I'm telling you these guys are very good and are not generous by nature!Almost the only risk left with Geron is that it won't achieve the absurd optimistic heights immediately that some have called for.
From SA Comments:
Analyst X
"I've been in Geron for 20 years and three weeks now, and I'm not surprised at all by today's events. Old-timers on this board know I used to post frequently, and that I listen closely to every Geron presentation, and continue to follow the discussion here even though I now post infrequently. That doesn't mean what I'm about to say is right, but I would appreciate the benefit of the doubt that it is at least well considered.
Basically, I see it as likely that given everything JNJ has been doing, posting the job description, including imetelstat in their compassionate use program, and listing imetelstat in all their presentations, with MDS added into today's presentation, one of two scenarios is likely taking place behind the scenes as regards to the CD, and neither of them make JNJ's actions today seem odd to me.
The first of the two scenarios is that JNJ and Geron are in negotiations regarding either altering their collaboration agreement, or a buyout of Geron. If they are in such negotiations, it would only strengthen Geron's hand in these negotiations with JNJ if JNJ put a lot of sizzle regarding imetelstat into today's presentation. But it would also be acting in bad faith (to my mind in a very counterproductive way from a corporate standpoint) if they took imetelstat out of the presentation entirely,- that would be tantamount to manipulation if they do intend to move forward one way or another, so if they are in negotiations it seems to me a very moderate action to settle on adding it to the slide deck in a way which is consistent with their intent to explore imetelstat in a minimum of MF and MDS going forward and then saying they aren't going to talk about it today. So by issuing essentially no comment on top of what they put in the slide deck, they've done more than the minimum to stay on the fair side of being in good faith, without doing something contrary to their own self interest in weakening their own hand in the negotiations by breaking news today that would drive Geron's share price up and thus weaken their hands in any negotiations. If they are bargaining with Geron right now, which is a distinct possibility, either over renegotiating the Collaboration Agreement in the hopes of gaining better terms for themselves if imetelstat becomes a blockbuster, or over the terms of a buyout, why would they want to drive Geron's market cap sky high today? It's not as if they are ignorant about the circumstances driving the stock,- a devoted fan base as exemplified by this board combined with 34% of the shares sold short. If there are serious negotiations going on you can bet the people conducting them are aware of these dynamics, and you can bet they were controlling precisely what was said and not said today. The palpable nervousness in the voice of the gentleman as he responded to the question about imetelstat today in the Q&A certainly seemed to me indicate that he had been told in no uncertain terms to not say much about imetelstat today.
Alternatively, if there actually aren't serious negotiations going on right now, and the corporate wheels at Janssen (as YD Nguyen suggests on the thread of OOI's September to Remember article) are grinding slowly simply because they have until the end of Q3 to announce the decision, then that also can explain the inclusion of imetelstat on the slides without it being included in the comments. It's on the slides because it is in the plans, but it can't be talked about because the people officially making the CD decision say it can't be discussed until the decision has been announced. I know that sounds very boring, and un-conspiracy-theory like, but I agree with Y D Nguyen that it would not be unusual at all for a big corporation to act this way.
So to me, there are two very likely scenarios if JNJ plans to continue with imetelstat that explain JNJ's actions today quite rationally and so I'm not surprised about today's actions.
Best to all longs, especially those who measure their time following this story in decades!
AX"
I've been silently following on this message board on this stock for several months. I was holding 10k GERN shares priced at an average of 5.05 and I added 5k more today at 6.08 and another 50 $6 call contracts for next March at $1.80. I added more today because the price reaction is ridiculous today. I make this statement not because I am pumping the stock but rather the up and then down today was based on NOTHING.
1. So J&J mentioned GERN's drug on one slide - we already know they are considering this drug so this is a non-event (the jump up to $7 was based on nothing)
2. J&J did not mention GERN or GERN's drug when they covered the slide mentioned in number 1 above - and this means what? NOTHING. In fact, one could argue that they specifically did not mention anything because they are in talks with GERN about a wide variety of things including pricing and next steps where they or GERN cannot mention anything.
3. The question that was asked post conference led to a response, "we are evaluating the data and will be making a decision by the end of the month". This was a total dodge - what exactly was stated in that sentence that is negative (or positive)? NOTHING. Yet the share price deteriorates to $5.80? What was stated is known and is the same fact yesterday as it will be tomorrow AND for every day until a decision is announced.
4. Based on all of the negative sentiments created on NOTHING, AF tweets a perfectly orchestrated tweet stating the same thing he has been saying for months. THIS WAS NOT NEW it is the SAME OPINION AS HE HAD YESTERDAY. Yet due to the fragile mindset of the weak retails the share price collapsed to $5.10.
GET A GRIP PEOPLE. Will this drug by GERN get continued? I do not know but I believe it will be based on my own opinion and the material I have read. My opinion is no more significant or relevant than AF's opinion but it appears that people who publicly state that AF is a clown etc. do not act that way when he puts out a meaningless quote in the midst of a mindless selloff. Again, I have to repeat that absolutely NOTHING happened today that warrants the price collapsing to $5.10 (incidentally, we have recovered to $5.80 at the current moment so the market after the fear subsides agrees with me).
As for the other "opinions" being expressed by some -
A. Do I see a buyout for $100s of dollars by the end of the month - please - that is not very likely.
B. The continuation decision will move us to $50 - not likely. I would be pleased if we move into the double digits AND maintain that level. I believe this will happen and specifically $10-$11. Could it go higher - absolutely IF THE DATA IS UNEXPECTEDLY GOOD.
I will finish by saying, shorts are not stupid and they are very well organized. They know that fear is a powerful force that can get otherwise rational people to behave totally irrationally as we saw today. Do not discount the shorts nor believe that they do not have a plan to extract themselves out of their positions. Instead - focus on the facts, if the facts are good then the stock price will follow an upward trajectory. I won't state the obvious if the facts are not good. Let's look forward to the actual news event - the continuation decision.
BTW: the next short attack which I started hearing today is the message, "so what if they get continued - now we need a phase 3 trial which is years away so this is dead money till then". This sentence, if the continuation decision happens, will be the next short cry to keep the share price tempered.
Good luck to all of you.
Spockie YB.
Adam F. tweeted ( first time he wrote ,, will see I'm right or wrong,, ) a huge buy signal; basically telling shorts don't blame him if there's a 50-50 chance of CD approvals within the next couple weeks.
I am confident to say the least. Reasons for affirmative CD if not Buyout (To my own surprise, I am now more inclined than ever to assume the latter:
1. Latest data of Imet concluded and available in May 2018, a discontinuation by JJ would have been confirmed weeks if not months ago.
2. Financially: Lack of inside sales of Geron employees, barring 1 automatic sale, despite epic run YTD is extremely bullish.
3. On Sept 4 JJ JJ placed imetelstat on their compassionate use list. With 5 months to review latest data, you can effectively conclude that JJ approves of Imet’s results otherwise this move would never have been made.
4. Finally, Imet’s involvement in JJ’s deck today, 3 slides: 5 Job posted .Strategic partnership, 15 as a potential filing, 24 PRODUCTS APPROVED/FILED OR PLANNED FILINGS 2017-2021. Again, if JJ was not interested in CD or full on acquisition, they would not include Imet in the presentation, period, let alone multiple times. It’s clear JJ is proud to be sponsoring this drugs
p.s. Job posted .
SHORTS ? How are you ???
Ameritrade is - shake margined shares by raising Equity Requirements !!!!!
Questrade has the borrow rate at 106.11%. Let that sink in. 106.11%
This is the time that the shorts are seeing their profits (if any) dwindle and the number of shares they have shorted evaporate at the rate over 1 share per 100 per day. That's a fact. Can't counter that.
This is the beginning of the end for the shorts. When this thing blows, it's going to be the fastest rocket ship you have ever seen, and I might have my 10k shares GTC @ $200 actually pay out.
Cover now before you lose your house.
breakthru
Points from Q2 2018 Geron Corp Earnings Call on July 31, 2018
In connection with Janssen's Continuation Decision [CD] for further development of Imetelstat:
- Janssen CD time frame: GERN expects by the end of the 3rd quarter 2018 (approx. 30Sept18).
- Data Package from Janssen (IMbark primary Analysis & IMerge preliminary results including additional cohort of 25 patients recently enrolled).
- GERN does not expect to provide any further comments on the contents or the timing of this data package prior to Janssen's decision, except under certain circumstances.
-- For example, if the Joint Steering Committee comprised of member of both Janssen and Geron determine that the data do not support further development of imetelstat, then we would expect to disclose such a conclusion even prior to a Janssen decision.
- Regarding data presentation: to maintain the customary medical conference embargo for such potential presentations, we do not anticipate data from either trial to be publicly presented before Janssen notifies us of their decision.
As an opinion, a "sign post" along the CD road to watch is:
1. If a prior CD announcement of - "data do not support further development of Imetelstat"- it's game over.
2. If item #1 above does not occur, than a favorable "Data Package" is highly likely. Assuming the "Data Package" is delivered to GERN 2 to 4 weeks prior to the end of the 3rd quarter, the risk is progressively reduced as the 3rd quarter CD end date approaches.
3. If item #2 occurs, then I would expect the stock price to rise accordingly during the 2-4 weeks prior to the CD.
4. Yes, there are other scenarios. However, given all the prior articles and data presented to date, I tend to lean towards a positive Janssen CD.
Disclosure: I am long GERN. YB .
Nice story : The year 1991. I wanted to buy DELL. I tried to convince a coworker to take a loan out of our SIP for about $10,000 and invest in DELL as I thought everyone would eventually own a PC or 2. He told me it was too risky and that Mike Dell was constantly selling $100,000 worth of stock on a regular basis. I reluctantly agreed and never pulled the trigger. That cost me over $5 MILLION by 2001. Lesson: insiders selling is meaningless. Look at NVCR. GERN's GC selling his options is meaningless.
Fast forwarded to 2017. I bought SRPT for 11 prior to the ADCOM. I listened to the presentation. The doctors and the parents. The final vote went against SRPT. I panic sold at 9 and watched the stock tank to about 6.5 and then start to rise again. I panic bought at 9.5. Later it was posted that one of the people in charge at the FDA (Kathleen?) was seen at a nearby hotel taking smiling pictures with some of the inflicted boys. Why would she do that AFTER such a bad vote. I told my wife that this was a "tell". The FDA was going to approve the drug. When SRPT reach 24 I lost my conviction and sold. How was the FDA going to vote? They approved the drug and SRPT is now north of 120.
It's all about reading the tea leaves. The JNJ job posting is THE TELL. There was another LinkedIn posting where the individual said he was working on the LAUNCH of Imetelstat.
I've been in GERN since the embryonic stem cell days. I've suffered very long. No More. JNJ will continue. PERIOD. CD or BO? It doesn't matter. GERN will go UP from here. SA board
GERON BLAST OFF !!! countdown
https://www.timeanddate.com/countdown/launch?iso=20180904T0950&p0=179&msg=GERON+BLAST+OFF&font=cursive
The Moment of Truth Approaches for Geron Corporation (NASDAQ:GERN)
Aug 29, 2018 | Business
https://fdaheadlines.com/the-moment-of-truth-approaches-for-geron-corporation-nasdaqgern/
ALL do your own DD, but here is a straight out simple fact. Do not lose sight of this one. Bloomberg posted the JNJ response of the job posting being a non-event one way or another for the imetelstat position at 12.51PM EST. That was right at about $4.95/shr. Instead of bleeding off in to a death spiral down to unchanged for the rest of the session, you might notice for 3 hours and 10 minutes after that the stock only traded higher, finally finishing at the close we know of $5.19/shr. For over 3 hours in to the close it only traded higher. Don't tell me today wasn't a good sign and that JNJ telegraphed the positive continuation decision. Any other change of story like that would have sent this back to $4/shr. even in 30 minutes or less. We go higher. AFTER HOURS $5.31
p.s. J&J still not removed from Job post - (IMETELSTAT) The Strategic Pricing Manager for Imbruvica & Imetelstat will work closely with the Compound Market Access Leaders, the EMEA Pricing Hub, Global Pricing and EMEA Operating Companies in managing strategic pricing within the Hematology therapy area.
•The indications of interest for Imbruvica and Imetelstat are as follows:
•Imbruvica tablet formulation
•Imbruvica 1L+ Waldenstrom’s
•Imbruvica 1L CLL elderly, unfit (I + G)
•1L DLBCL (non-GCB)
•Imbruvica combination with rituximab
•Imbruvica DLBCL front-line
•Imbruvica CLL front-line
•Imbruvica chronic GVHD
•Imbruvica CLL young and fit
•Imbruvica FL relapsed/refractory
•Imbruvica MCL front-line maintenance
•Imetelstat Lower Risk MDS
•Imetelstat AML induction ineligible
https://jobs.jnj.com/jobs/00001DCC?lang=en-us
40,000,000 MILLION Shares traded on one (1) little job opening post....imagine what real new will do to this stock??
J&J reaction via SA
“J&J told Bloomberg that the job posting does not have anything to do with its licensing deal with Geron. The job specs encompass the range of responsibilities that are "consistent" with Janssen's blood cancer portfolio. GERN is still up 27% heading into the last hour of trading“. LOL.?? haha
Adam F.'s tweet had an effect and the stock dropped .60 cents right after the tweet.
He now has the weekend to dream up another negative reason why Gern should be shorted.
It looks like his following is substantial and until the continuing decision is announced he will
have a negative effect on the share price. The investigation by the various lawyers awhile back
seemed to be coordinating their activities with Adam. Looks like Collusion to me. Y.B
you have to see doctor ASAP !!! ,, DOGS BARKING , BUT CARAVAN GOES ,,
Whoa. State Street added 9.2 million shares as of June, bringing their total holdings to 15.5 million. And Blackrock added 1.5 million bringing their total to 13.4 million. FMR sold 4 million, but they still hold 15.5 million. Vanguard added 700k and now holds 8 million total.
Just these four institutions own about 30% of GERN's outstanding. These guys manage trillions so it might sound like a lot in the absolute sense, but it says a lot that they own 30% of this tiny bio. They want GERN because the market wants GERN.
Amazon was unprofitable for many years..
How many biotech companies do you have that spend zillions of dollars on trials without ever making a dime??? they consistently lose money for years all in hope that the drug will work...at least here I see that their investment is paying off and that they are growing at an incredible rate...someone will pay for this growth...
I noticed the reduced cash also, but they do have over $2.2 million in inventory to offset half of it. During the call they said they like to keep 6 months worth of product on hand and as we grow the value related to inventory will also grow. Last quarter they only had $1.6 million in inventory and they sold almost $7 million worth of product in the second quarter. All in all it looks like they are managing their money wisely to me especially since they are bringing new product to market at the same time.
They covered their losses, grew the company, and set them selves up for the next quarter. If you want to check the numbers look at the Q2 press release from last night and compare it to the Q1 press release that can be found on their website. The numbers are all there. I have seen many companies with higher market caps that burn more each quarter than they could ever dream of covering. This is still a sound investment and it only gets better as the price drops as long as you have the money and the tolerance to invest more. EV Y.B.
keep dreaming.
They people not investors - They cry shorts players and time losers...…...
What are you talking about ??? - (A lot of selling pressure. But seems people are jumping each other to sell cheaper so as to get out) ………….. Vol little over 2Mil . shares all ASK 5000 shares , MM play game with weak hands + Market down today … p.s. keep dreaming 0.085 cents..
Team - thanks for your reactions. Mostly I appreciate the civility and thoughtful comments for and against. If nothing else, I love the diversity of thought on this MB. We all bring something of value to this board and our discussion. I will always respects you even if I disagree with your assessment.
Again, I am a supporter of Innovus or I would not have invested so heavily. I shared with you all yesterday that the market will not be impressed with the revenues or the guidance and the SP will take a hit today. This morning I am a little concerned (as I went through the financials last night) about our accumulated deficit of $39 million since inception; I am a bit concerned that we started Q2 with $5 million in cash-on-hand and now as of 8/10, we are down to $1.9 million cash-on-hand; I worry that they may have to sell debt securities or sell equity in the next few months to raise fast cash to run the business etc. I also think that the CEO should reduce his salary compensation for another 12-months because his salary, vacation, bonus and benefits are all part of the long-term liability and negatively impact the income statement. I appreciate the fact that he is actually deferring his hefty $1.4 million annual salary but it is still being accrued and hits the P&L as an expense. I am not the CEO of Innovus so it is not my place (as a shareholder) to dictate what he does but many CEO's sacrifice in the infancy stage of the company only to reap heavily in the long-run. Q2 also shows $225,000 in stock option grants which again show-up as a liability and hurts the EPS line item.
This company is in a growth mode as they have gone from 6 employees in 2017 to 19 employees in 2018. This is a fairly large expansion. Their sales expenses are growing commensurately and that is explainable. What worries me perhaps more than anything is dilution. This is a real probability for Innovus in the next 6-12 months as it burns through cash to support the operation. While we are retiring many notes (a big part of their income statement expenses for Q2), my concern is that they will sell more debt instruments and that will simply replace the old debt and further delay their quest for profitability.
Lastly, if I could give Dr. Damaj a bit of advice, it would be to stop taunting the market-makers and just focus on your business and your own flight plan. Stay in your swim lane and don't get emotionally tangled. Let your stock performance take care of them down the road.
Sorry for the lengthy post; this is it. I will see you all in a few months. Ciao from SYD Y.B.
Geron Co. (NASDAQ:GERN) announced a quarterly dividend on Tuesday, August 7th, RTT News reports. Shareholders of record on Tuesday, August 21st will be paid a dividend of 0.16 per share by the biopharmaceutical company on Tuesday, August 28th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 16.37%. The ex-dividend date is Monday, August 20th
https://xnewspress.com/2018/08/07/geron-co-gern-announces-quarterly-dividend-of-0-16.html
If, If , … ? But, We concluded that "the risk-reward of the stock at current levels merits the attention of long investors... and further, we believe that Janssen considers imetelstat to be a core part of its pipeline and view the continuation of the Geron agreement to be likely." Based on yesterday's comments from JNJ Chairman and CEO Alex Gorsky, we reiterate our view that Geron remains a priority for Janssen and JNJ.
https://www.equities.com/news/geron-s-imetelstat-reaffirmed-as-a-priority-for-johnson-johnson
•Median Overall Survival Keeps Growing In Unprecedented 25+ Months In The Myelofibrosis iMbark Trial.
•iMerge Part 1 Expansion Phase is now beyond critical 8 Week point for transfusion independence.
•Shorts run out of supply for stocks to cover as 2015 ATM program is now complete; shares available will now dry up very quickly.
Today's Q4 announcement confirms the strong collaboration between Geron (GERN) and Johnson and Johnson (JNJ) remains strong and is moving forward. Median Overall Survival has not yet been reached in the Myelofibrosis "MF" trial iMbark and iMerge has now passed the 8 week critical point. All systems go, as they say, for the collaboration and for Geron shareholders.
https://seekingalpha.com/instablog/3163201-medtechbio/5157556-systems-go-geron-jnj-imerge-imbark-trials-mf-mds
Look at GERN, it is going to be bought out by JNJ by end of September 2018
Team - don't try to micro-analyze this stock on a daily basis if you are truly an investor in Innovus. If you have plans to make "real" money as opposed to a few pennies, then don't fret over the daily up and down (ask and bid) transactions. I know we have some smart people on this board who like looking at Level 2 and try to analyze why someone is selling at 0.13 or 0.14 cents two weeks before the earnings call when we have historically seen a slight uptick leading up to the call especially when we already know Q2 had good top line revenues. This stock will go up. Period. But have the patience to just wait till at least Q1 2019 earnings call when we hope to have a better picture on 2018 full-year sales, profitability, EPS and news about other products in the pipeline. Unless this is your only investment and you have nothing else on your docket, refrain from getting excited about the day-to-day, fractional movements. From all indications, it appears we have a new support line around 0.15 and now hopefully, we will go up from here in the next 6-7 months. Any way, this is just my thought process and I feel completely at peace with the investment I have made in Innovus. This stock will be above a $1 in due time. SYD . Yahoo board
MannyFresh - Time Loser your opinion is = 0. with your prediction you have to see Doctor ASAP !!!
New York Times ,Saturday, July 21, 2018
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
https://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201807190605BIZWIRE_USPRX____BW5039&feedID=600&press_symbol=83994
INNV. New York Times ,Saturday, July 21, 2018
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
https://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201807190605BIZWIRE_USPRX____BW5039&feedID=600&press_symbol=83994
New York Times ,Saturday, July 21, 2018
Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic
https://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201807190605BIZWIRE_USPRX____BW5039&feedID=600&press_symbol=83994
I spoke to Geron IR. That information is several years old. OLD NEWS!
Time Loser are you back ? - is GOOD sign , your opinion is 0 .
WHO SOLD $3.15 ? HOW STUPID YOU ARE !!!!! LISTEN MORE SHORT....S
Innovus Pharmaceuticals, Inc. (OTMKTS:INNV) Launches Higher on Major New Pilot Program
By James Hudson -
July 20, 2018
https://oracledispatch.com/2018/07/20/innovus-pharmaceuticals-inc-otmktsinnv-launches-higher-major-new-pilot-program/
Here's the list of drugs J&J plans to file for approval over the next four years that could hit that blockbuster threshold, including cancer and depression treatments:
•guselkumab - psoriasis (Filed for approval in 2016)
•sirukumab - rheumatoid arthritis (Filed for approval in 2016)
•apalutamide - pre-metastatic prostate cancer
•esketamine - treatment-resistant depression
•talacotuzumab - acute myeloid leukemia, a type of blood cancer
•erdafitinib - solid tumors
•niraparib - prostate cancer
•imetelstat - myelofibrosis, a bone marrow disorder
•pimodivir - influenza A
•lumicitabine - respiratory syncytial virus (RSV) infection
•JNJ-7922 - adjunctive treatment for major depressive disorder
http://www.businessinsider.com/johnson-and-johnson-blockbuster-drug-potentials-by-2021-2017-5
Geron's Imetelstat Reaffirmed as a Priority for Johnson & Johnson
Wednesday, 18 July 2018 15:04 (EST)The chart below summarizes Janssen's pipeline of new molecular entities (NMEs). We note that Janssen continues to list Geron's imetelstat as the first oncology asset in its pipeline. Reinforcing this priority, Mr. Gorsky cited two areas of oncology—prostate cancer (for which Janssen earned an FDA approval earlier this year) and hematology (which is obviously Geron's area of focus)—as Janssen's principal catalysts for growth for the remainder of this year. We believe that the mentions of imetelstat at the top of the priority list in the pipeline and at the top of Mr. Gorsky's comments on Janssen are not merely coincidental; rather, we take this as a solid indicator of Janssen's commitment to imetelstat as a potential billion dollar therapeutic
https://www.equities.com/news/geron-s-imetelstat-reaffirmed-as-a-priority-for-johnson-johnson
206K shares long …..